Psilocybin Alpha reports..

The German Government has approved a Phase 2b study on psilocybin for treatment-resistant depression, and is providing millions of Euros to this latest psychedelic research project.

Germany’s Federal Institute for Drugs and Medical Devices has approved a study on the Efficacy and Safety of Psilocybin in Treatment-Resistant Depression, known by the shorthand ‘EPIsoDE’. This marks the first psilocybin depression study in Germany since the 1970s.

The phase 2b two-centre study will investigate the safety and efficacy of psilocybin in a controlled, randomised double-blind design. Specifically, a therapeutic dose of psilocybin (25mg) will be compared to an active control dose of psilocybin (5mg) and niacin. A second therapeutic dose will be administered six weeks after the first. The study expects to have 144 participants.

Read their full report at.  https://psilocybinalpha.com/news/psilocybin-for-depression-study-approved-and-funded-by-german-government?utm_source=Psilocybin+Alpha&utm_campaign=da0a4e7bb6-EMAIL_CAMPAIGN_2020_11_20_11_24&utm_medium=email&utm_term=0_744c72e063-da0a4e7bb6-382540561